Home > Boards > US Listed > Medical - Drugs > Merck & Co. Inc. (MRK)

KEYNOTE-181 in second-line esophageal cancer hits primary OS

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 720
Posts 108,608
Boards Moderated 21
Alias Born 09/05/02
160x600 placeholder
DewDiligence Member Level  Wednesday, 11/14/18 08:25:55 AM
Re: None
Post # of 469 
KEYNOTE-181 in second-line esophageal cancer hits primary OS endpoint in PDL1+ subgroup, misses in overall trial (ITT population):

https://www.businesswire.com/news/home/20181114005229/en/Merck%E2%80%99s-KEYTRUDA%C2%AE-pembrolizumab-Significantly-Improved-Survival-OS

The trial tested Ketruda monotherapy vs standard chemo. No HR figures have been disclosed yet.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist